NCT00977015CompletedPhase 1
An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers.
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Plasma pharmacokinetic parameters: AUClast and Cmax
Study Overview
Brief Summary
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 21 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male and/or female subjects between the ages of 21 and 55 years.
- •Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •A positive urine drug screen.
- •History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
- •Pregnant or nursing females.
Arms & Interventions
Treatment A - PF-04764793
Experimental
PF-04764793 using inhaler A
Intervention: Treatment A (Drug)
Treatment B - PF-04764793
Active Comparator
PF-04764793 using inhaler B
Intervention: Treatment B (Drug)
Outcomes
Primary Outcomes
Plasma pharmacokinetic parameters: AUClast and Cmax
Time Frame: 48
Secondary Outcomes
- Plasma pharmacokinetic parameters: AUC0-12, AUC0-24, AUCinf, Tmax and terminal half-life.(48)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder InhalersHealthyNCT00928278Pfizer36
Completed
Phase 1
This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder InhalersHealthyNCT01272375Pfizer48
Completed
Phase 1
A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.HealthyNCT00862667Pfizer36
Completed
Phase 1
A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder InhalersPharmacokineticsNCT00867282Pfizer36
Completed
Phase 1
A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder InhalersPharmacokineticsNCT01181700Pfizer42